Detection at a Cost: How Overscreening in Privileged Health Systems Drains Diagnostic Resources from High-Burden Underserved Communities
The Paradox at the Center of American Preventive Medicine
American public health has long championed early detection as an unambiguous good—a cornerstone of preventive medicine with the intuitive appeal of catching disease before it becomes catastrophic. Yet a growing body of epidemiological and health systems research complicates that narrative in ways the field has been slow to confront. When screening is concentrated in populations with the lowest disease burden and the greatest existing access to care, and when diagnostic thresholds are progressively lowered in response to insurer incentives and clinical culture rather than population-level evidence, the result is not simply overdiagnosis in isolation. The result is a resource competition—one that privileged patients are structurally positioned to win, and that low-income communities with genuine, unmet detection needs are structurally positioned to lose.
This is the screening paradox: a healthcare system that expands its diagnostic gaze most aggressively where the marginal benefit is smallest, while populations carrying the highest burden of undiagnosed chronic disease remain outside the frame entirely.
Overdiagnosis Is Not a Neutral Clinical Event
The clinical literature on overdiagnosis—the identification of conditions that would never have caused symptoms, harm, or death in the patient's lifetime—has grown substantially over the past two decades. Studies examining prostate cancer, thyroid cancer, breast cancer, and a range of metabolic conditions have documented the phenomenon with increasing precision. What that literature has been less forthcoming about is the downstream distributional consequence of overdiagnosis at the population level.
Each overdiagnosed case generates a cascade of clinical activity: confirmatory imaging, specialist consultations, biopsy procedures, follow-up appointments, and in many instances, treatment with real iatrogenic risk. This activity is not costless in aggregate. It consumes pathology laboratory capacity, radiologist time, endocrinology and oncology clinic slots, and health system administrative bandwidth. In markets where these resources are already constrained—which describes the majority of safety-net and federally qualified health center (FQHC) environments across the United States—the absorption of that activity by insured, higher-income patients in adjacent or overlapping health systems has measurable consequences for availability and access.
A 2022 analysis published in Health Affairs estimated that unnecessary follow-up procedures stemming from low-value screening in commercially insured populations contributed meaningfully to specialist appointment backlogs in mixed-payer regional health markets. The mechanism is not conspiratorial; it is structural. Specialists in private practice and academic medical centers preferentially schedule patients with commercial insurance, and when those schedules fill with overdiagnosis-driven follow-up, Medicaid and uninsured patients—who often present with more advanced, genuinely symptomatic disease—wait longer or do not receive appointments at all.
Chronic Disease Detection and the Geography of Diagnostic Neglect
The consequences of this structural competition are perhaps most legible in the epidemiology of chronic disease. Type 2 diabetes and hypertension offer instructive cases. Both conditions are subject to ongoing debate about optimal screening thresholds, and both have seen diagnostic criteria shift in ways that expand the diagnosed population in clinical settings serving insured patients.
The American Diabetes Association's adoption of HbA1c thresholds for prediabetes identification, for instance, has dramatically enlarged the population receiving metabolic monitoring and preventive counseling in primary care settings with robust infrastructure. In well-resourced practices, this expansion is manageable. In FQHCs and rural health clinics operating at or beyond capacity, the same expanded criteria create unfunded mandates for follow-up that the clinical workforce cannot absorb. The result is a bifurcated landscape: commercially insured patients in suburban markets receive prediabetes counseling and repeat laboratory monitoring for conditions that may never progress, while uninsured patients in urban cores and rural counties go unscreened for frank diabetes until they present in emergency departments with end-organ complications.
Centers for Disease Control and Prevention surveillance data consistently document this disparity. Undiagnosed diabetes prevalence is substantially higher among uninsured and low-income populations, and the gap has not closed despite decades of public health messaging. What surveillance data do not typically capture is the degree to which health system resource allocation decisions—shaped in part by the diagnostic volume generated in insured markets—contribute to that persistent gap.
Cancer Screening and the Maldistribution of Imaging Infrastructure
In oncology, the resource competition generated by expanded screening is perhaps most consequential. Mammography, colonoscopy, low-dose CT lung screening, and cervical cancer surveillance all require physical infrastructure, trained technicians, and interpretive specialists. That infrastructure is not uniformly distributed across the American healthcare landscape, and its distribution is shaped by market forces that reward high-volume, insured patient populations.
Mammography capacity, for example, is disproportionately concentrated in suburban and urban markets with high rates of commercial insurance coverage. Rural counties—where breast cancer late-stage diagnosis rates are elevated—frequently lack accredited mammography facilities within reasonable travel distance. The expansion of screening recommendations to younger age groups and shorter intervals in clinical guidelines, driven largely by evidence generated in well-resourced populations, increases demand on existing facilities without proportional infrastructure investment in underserved regions.
The consequence is a form of diagnostic triage that operates beneath the level of explicit policy: imaging slots fill in markets where patients can pay, follow-up capacity concentrates around those markets, and communities with genuine, high-burden unmet detection needs receive the residual. Late-stage cancer diagnosis rates in low-income and rural populations reflect not only barriers to individual healthcare access but also the maldistribution of a diagnostic apparatus that has been shaped by and oriented toward a different patient population.
Toward a Population-Level Accounting of Screening Value
Addressing the screening paradox requires a reorientation of how the public health and clinical research communities evaluate the value of screening interventions. Current frameworks overwhelmingly assess screening benefit at the individual or cohort level—does this patient benefit from this test? A population-level accounting would ask a different and more uncomfortable question: given finite health system capacity, does expanding this screening protocol in this population generate net benefit when the opportunity costs to other populations are incorporated?
Such an accounting would not require eliminating evidence-based screening in any population. It would require honest epidemiological analysis of where detection needs are greatest, where screening capacity is most deficient, and how clinical incentive structures—including fee-for-service reimbursement models that reward diagnostic volume regardless of marginal clinical benefit—contribute to the maldistribution of that capacity.
Federal and state health agencies, including the Centers for Medicare & Medicaid Services and state health departments administering Medicaid programs, have levers to influence this distribution. Certificate-of-need reforms, targeted infrastructure grants for FQHC imaging and laboratory capacity, and reimbursement structures that reward detection in high-burden rather than high-volume populations are among the policy instruments available. What has been lacking is the political and institutional will to apply them—and, prior to that, the epidemiological framing that makes the problem visible as a distributional one rather than simply a gap in individual access.
The screening paradox will not be resolved by more screening. It will be resolved by a more honest reckoning with who screening serves, what it costs, and who bears the burden when the costs are distributed unequally across an already stratified health system.
